Abstract
Introduction
Myasthenia gravis (MG) is a classic antoimmune disease affecting neuromuscular junctions of striated muscle. Immunization of different animal species with acetylcholine receptor (AChR) and complete Freund's adjuvant (CFA) results in an animal model of MG named experimental autoimmune myasthenia gravis (EAMG). The prevailing notion is that the impaired neuromuscular transmission in both MG and EAMG is caused by antibodies against AChR (1) (2) (3) . Several lines of evidence suggest that cell-mediated immune effector responses may also participate in the pathogenesis of MG and EAMG. Firstly, there is no direct correlation between the anti-AChR antibody levels and the clinical severity of both human MG and EAMG (2) (3) (4) (5) . Between 10 and 15% of patients with MG have no detectable anti-AChR antibodies in their serum (3) . Secondly, focal accumulations of mononuclear cells have been observed in striated muscle specimens from MG patients and EAMG rats (6) (7) (8) (9) . Thirdly, antibody-and complement-dependent cell-mediated cytotoxicity does occur in EAMG in rat (8, 9) .
The production of anti-AChR autoantibodies is dependent on T cell help (10) (11) (12) . In the immunopathogensis of MG and EAMG, B cells are expected to serve as antigen-presenting Correspondence to: F.-D. Shi Transmitting editor: L. Steinman Received 30 March 1998, accepted 9 June 1998 cells (APC) for autoreactive T cell priming and as effector cells that secrete anti-AChR antibodies. To evaluate the extent at which abnormal B cell responses against AChR operate in the pathogenesis of EAMG, we compared the development of EAMG in susceptible C57BL/6 (B6, H-2 b haplotype) mice (4) and in B6 mice rendered deficient of B cells (µMT). We found that µMT mice were completely resistant to EAMG, as compared to wild-type control mice. B cells are thus essentially required for the genesis of EAMG in mice, while the immune effector role of other cell types, if there is any, seems not to be sufficient for the genesis of EAMG.
Methods

Mice
B6 µMT mice, originally obtained from B & K (Universal, Hull, UK), were generated by targeted disruption of the µ heavy chain transmembrane exon (13) . Inbred B6 mice were obtained from Bommice (Ry, Denmark) and used as a wildtype control. Mice were bred and maintained under pathogenfree conditions in the animal facilities of the Huddinge Univer-sity Hospital. All mice used were females and 8-12 weeks of age. Animal experimental procedures were in compliance with institutional guidelines.
Antigens and synthetic AChR α chain peptide AChR was purified from the electric organs of Torpedo Californica (Pacific Biomarine, Venice, CA) by affinity chromatography on an α-cobrotoxin-agarose resin (Sigma, St Louis, MO) (14) . The isolated product was pure as judged by SDS-PAGE. The purified Torpedo AChR was used to induce EAMG and for in vitro culture. Mouse muscle AChR (M-AChR) was extracted from normal B6 mouse (14) for use as antigen to detect anti-mouse AChR antibodies. Myelin basic protein (MBP) for use as control antigen was purified from normal mouse brains (15) . Synthetic dominant peptide (α146-162) Enumeration of AChR and α146-162 reactive IFN-γ secreting cells
A solid-phase enzyme-linked immunospot (ELISPOT) assay was adopted (17) (18) (19) . Nitrocellulose-bottomed microtiter plates were coated with 100 µl IFN-γ capture antibody (DB1; Innogenetics, Genth, Belgium) at 15 µg/ml. Aliquots of 200 µl of cell suspension containing 4ϫ10 5 MNC were added to individual wells in triplicate, followed by antigen (AChR or α146-162 or MBP) or the mitogen Con A (Sigma) in 10 µl 
aliquots to a final concentration of 10 µg/ml of AChR or MBP or peptide, or 5 µg/ml of Con A. These antigen or mitogen concentrations resulted in optimal stimulatory effects in preliminary experiments (17) . After 48 h of culture, the wells were emptied. Secreted and bound IFN-γ was visualized by sequential application of polyclonal rabbit anti-rat IFN-γ (Innogenetics), biotinylated anti-rabbit IgG and avidin-biotin peroxidase complex (ABC) (both from Dakopatts, Glostrup, Denmark). After peroxidase staining, the red-brown immunospots, which corresponded to the cells that had secreted IFN-γ, were enumerated in a dissection microscope. To calculate the numbers of T cells responding to a particular antigen or mitogen, numbers of spots in culture without antigen added were subtracted from the values obtained after antigen or mitogen exposure. The data were expressed as numbers/ 10 5 MNC.
Detection of cytokine mRNA expression by semi-quantitative RT-PCR PILN MNC suspensions of 2ϫ10 6 cells/ml consisting of pools of equal amount of cells from five mice in each group, sacrificed on day 7 post-primary infection (p.i.), were cultured for 24 h with or without AChR (final concentration 10 µl/ml). The cells were washed, divided into aliquots of 5ϫ10 6 cells and stored at -70°C until use. mRNA was extracted from 5ϫ10 6 MNC using a QuickPrep Micro mRNA purification kit (Pharmacia Biotech, Uppsala, Sweden). cDNA was synthesized using oligo(dT) 18 primer according to the manufacturer's instructions (Pharmacia Biotech). PCR primers for mouse cytokines (IFN-γ, IL-4 and IL-10) were designed by using Oligo 5.0 software (NBI, Plymouth, MN). The sequences of primers used are shown in Table 1 . A mouse β-actin gene was simultaneously amplified as a reference gene for normalization. All the primers used were fluorescence labeled. PCR amplification was performed in 10 µl of reaction volumes consisting of 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.2 µM primers, 1 µl cDNA and 0.25 U Taq polymerase (Pharmacia Biotech). Thirty amplification cycles were carried out by the GeneAmp PCR System 9600 (Perkin-Elmer, Foster City, CA), and each cycle consisted of 94°C 30 s, 55°C 30 s and 72°C 30 s, whereas annealing temperature for β-actin was 62°C. Amplified PCR products were pooled with the size standard (GenScan500; PerkinElmer) and analyzed on an automated DNA sequencer (ABI-377; Perkin-Elmer). The specific fluorescence intensity determined as peak areas by the sequencer parallels with copies of amplified products. Semi-quantitation of cytokine gene expression was represented as ratios of peak areas of cytokines and those of β-actin.
Enumeration of anti-AChR IgG antibody secreting cells
An ELISPOT assay was used with some modifications (19) . Briefly, wells of microtiter plates with nitrocellulose bottoms were coated with 100 µl AChR or MBP (10 µg/ml in PBS).
Aliquots of 100 µl cell suspensions containing 2ϫ10 5 MNC were added in triplicate to individual wells. After incubation for 24 h, the wells were emptied, followed by addition of rabbit anti-mouse IgG (Sigma), biotinylated swine anti-rabbit IgG (Dakopatts) and ABC. After peroxidase staining, the redbrown immunospots which corresponded to cells having secreted anti-AChR IgG were counted and numbers were standardized to numbers/10 5 MNC. Radioimmunoassay for measurements of serum anti-AChR antibodies Blood samples were collected from mouse tail vein just prior to immunization, and then on day 15, 45 and 75 after primary immunization. Serum anti-AChR antibody concentrations were measured by radioimmunoassay (14) . Briefly, 1 nM M-AChR was incubated with 2 nM [ 125 I]α-bungarotoxin (Amersham). To 1 ml of labeled M-AChR, 1 µl serum was added, followed by rabbit anti-mouse Ig (Dakopatts). The samples were centrifuged, washed and counted in a γ-counter. The AChR precipitated minus the background value permits calculation of the titer in moles of toxin binding sites bound per liter of serum.
Immunohistochemistry
Immunohistochemistry studies were performed on groups of 4 mice on day 15, 45 and 75 p.i. (20) . Cellular infiltrates were characterized in serial sections by incubation with the following mAb: rat anti-mouse CD4 and CD8 (PharMingen, San Diego, CA), and rat anti-mouse Mac-1 (Boehringer, Mannheim, Germany), followed by biotinylated rabbit anti-rat IgG (Vector, Burlingame, CA) and ABC (Vector). The numbers of macrophages, CD4 ϩ and CD8 ϩ cells were counted in transverse sections of five random fields of 1 mm 2 at a magnification of ϫ200 per marker and animal. Data from three sections of each muscle were pooled. The mean values for both limbs provide a mean value for each animal. The results were expressed per 1 mm 2 tissue area. For colocalization of cellular infiltration and AChR, the same sections were incubated with FITC-labeled α-bungarotoxin (Sigma).
Statistical analysis
Differences between the two groups were evaluated by Student's t-test. Differences between groups with respect to the incidence were analyzed with Fisher's exact test.
Results
B cell-deficient mice are resistant to EAMG induction
In the first experiment, 15 µMT and 17 B6 mice were immunized 3 times (days 0, 30 and 60) with AChR in CFA. Twelve B6 mice developed muscle weakness before (two mice) or after (10 mice) the first boosting. Among them, five mice exhibited mild or moderate muscle weakness. Seven mice deteriorated progressively and two of them died, while one was killed humanely for animal protection reasons. In contrast, µMT mice remained completely resistant to EAMG induction.
Only one out of 17 exhibited mild weakness and recovered around day 54 p.i. Two µMT mice died from anesthesia during the experiments. In a second experiment series with five B6 and six µMT mice, similar results were obtained. Four B6 mice but none of the µMT mice developed clinical muscle weakness (Table 2) .
AChR-specific IgG antibody-secreting cells and serum antiAChR antibodies were not detected in µMT mice The B6 mice immunized with AChR ϩ CFA had high numbers of anti-AChR IgG antibody secreting cells when examined on day 7 p.i. (mean 45 Ϯ 12/10 5 MNC). Such cells were not detectable in the immunized µMT mice. Consistently, levels of serum anti-AChR antibodies increased gradually in the B6 mouse, but were undetectable in the µMT mice (Fig. 1) . Numbers of MNC secreting IgG antibodies to the control antigen MBP were 0-1.2 cells/10 5 MNC in B6 mice and also absent in µMT mice.
Lymphocyte proliferation and IFN-γ-secreting cells were not affected µMT mice We immunized µMT and wild-type B6 mice with 20 µg of AChR in CFA. Seven days later, T cell responses of draining lymph nodes were analyzed in vitro for proliferation and levels of IFN-γ-secreting cells in response to AChR and the α146-162 peptide. As shown in Fig. 2 , MNC from µMT and wildtype B6 mice responded similarly to AChR and α146-162. Thus, AChR and peptide-specific T cell priming remained unaffected in µMT mice.
µMT and wild-type B6 mice have similar levels AChR-reactive cytokine mRNA To further define T cell functions in µMT mice, we examined cytokine mRNA levels in draining lymph node MNC by semiquantitative RT-PCR, which was shown in preliminary experiments to have high sensitivity and specificity (data not shown). Upon stimulation with AChR, µMT and control B6 mice had similar mRNA levels of IFN-γ, IL-4 and IL-10 ( Table  3 ). The mRNA levels detected after culture without AChR were low. No difference was found for mRNA levels of these cytokines between the two groups (Table 3) .
Muscular infiltrations
After immunization with AChR in CFA, macrophages, CD4 ϩ and CD8 ϩ cells, can be detected at day 15, 45 and 75 p.i. in muscle sections of control B6 and µMT mice (Fig. 3) . There was no obvious fluctuation in numbers of infiltrating cells at the three time points. There was also no difference in numbers of infiltrating cells between µMT and control B6 mice. The mean numbers were 31 Ϯ 11 cells/mm 2 for macrophages, 17 Ϯ 10 cells/mm 2 for CD4 ϩ cells and 3 Ϯ 1 cells/mm 2 for CD8 ϩ cells at the three time points in the µMT mice, and 27 Ϯ 14 cells/mm 2 for macrophages, 20 Ϯ 6 cells/mm 2 for CD4 ϩ cells and 4 Ϯ 2 cells/mm 2 for CD8 ϩ cells in the control B6 mice. Macrophages and CD4 ϩ cells, but not CD8 ϩ cells could be detected in muscle of CFA immunized mice (mean 2 Ϯ 2 cells/ mm 2 ) (Fig. 3a) . Most infiltrating CD4 ϩ cells and macrophages were localized in the vicinity of neuromuscular junctions (Fig. 3d) .
Discussion
We examined the role of B cells in the development of EAMG. µMT mice are completely resistant to EAMG induction, associated with no detectable anti-AChR antibody production, but normal T h functions. These results unequivocally demonstrated the absolute requirement of B cells and pathogenic anti-AChR antibodies in the genesis of EAMG, while the role of additional effector mechanisms may only act in cooperating B cells/antibodies in EAMG pathogenesis.
AChR-targeted neuromuscular interference can result from several autoantibody-mediated effects, including functional blockade, AChR cross-linking and complement activation (5) . Because of the poor correlation between antibody levels and severity of clinical disease, and the presence of inflammatory cells in muscle specimens in both MG and EAMG, it is not clear whether there exists a role of cellular immunity in MG pathogenesis. Further, depletion of CD8 ϩ T cells either by antibody or by gene knockout reduces the clinical severity of EAMG in Lewis rat and B6 mice (21, 22) . CD8 ϩ T cells are suggested to be involved as helper or effector cells in EAMG pathogenesis (21, 22) .
In human MG, anti-AChR antibody levels in different patients do not correlate with the severity of clinical muscle weakness, changes of the antibody levels in a given patient generally correlate well with changes in clinical disease severity (23) . Seronegative MG patients clearly have an antibody-mediated disorder since their serum IgG can passively transfer neuromuscular block to naïve animals and seronegative MG patients benefit from plasma exchange (3). It has become more and more evident that certain anti-AChR antibodies with high disease-causing potential, even when present at extremely low levels, can be highly detrimental to the functioning of the neuromuscular junction (5, (24) (25) (26) . Antibody-binding affinity, fine specificity for AChR epitopes and antibody isotypes determine the outcome of disease (5, 17, 25, 26) .
Infiltrating macrophages may contribute to muscle weakness by complement-dependent cell-mediated cytotoxicity in the early phase in EAMG in Lewis rat (8, 9) . However, this early phase of muscle weakness cannot be recorded in human MG and EAMG in mouse. Accordingly, only the chronic phase of EAMG in Lewis rats appears to represent an antibody-mediated event (27) . A major proportion of infiltrating macrophages is eliminated by apoptosis soon after their appearance (28) . Macrophage-associated cytokines but no chemokine mRNA-expressing cells could transiently be detected in muscle, which might indicate that the immune effector responses in muscle tissue in EAMG are not operated by infiltrating cells (20) . The paucity of T cells at or near the end-plates suggests that antigen presentation to T cells may not occur locally. A recent study, in support of this, showed that macrophages do not contribute to AChR loss in the effector phase of passive transfer EAMG (29) . Unlike in Lewis rat EAMG, we showed that muscle infiltrations of macrophages, CD4 ϩ and CD8 ϩ T cells are constantly low, and there is no difference in numbers of infiltrating cells in immunized wild-type B6 and µMT mice. The expansion and cytotoxic T lymphocyte activity have been shown not affected in the absence of B cell (30) . In MG patients, inflammatory infiltrations are not topographically related to end-plates and are not associated with severity of disease (6) . Taken together, the infiltrating cells in muscle are unlikely to have any pathogenic role in EAMG or MG. The reduced clinical severity of EAMG after CD8 ϩ T cell depletion or knockout may be the result of lacking the regulatory role of CD8 ϩ T cells.
The production of anti-AChR antibody is dependent on T cell help, provided by T h 1 and T h 2 cytokines and on crosslinking with the CD40 ligand (19) . In the present study, T cells proliferated normally to AChR and its myasthenogenic peptide α146-162 in µMT and control B6 mice, and both strains expressed similar levels of IFN-γ, IL-4 and IL-10. Therefore, B cells seem not to be required for priming naïve T cells in vivo. Our data support the hypothesis that the APC initiating in immune response to peptide antigen is most likely the dendritic cells, as suggested from recent studies (31) (32) (33) . T cell priming remained intact in this setting, suggesting that the resistance to EAMG induction in µMT mice is not the result of impaired T h functions.
µMT mice develop autoimmune encephalomyelitis and diabetes at a similar magnitude as wild-type mice (31, 33) . In contrast to these T cell-mediated conditions, µMT mice become completely resistant to EAMG induction. In accordance with this finding, we have also shown that CD40 liganddeficient mice had greatly impaired antibody responses and hence are resistant to EAMG induction (19) . Thus, the present studies reinforce the notion that B cells and autoantibodies are critical in EAMG pathogenesis and perhaps in human MG as well.
